News
RBC Capital Reiterates Outperform on Verve Therapeutics, Maintains $35 Price Target
28 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Verve Therapeutics: Q4 Earnings Insights
27 Feb 24
Earnings
Verve Therapeutics Q4 GAAP EPS $(0.69) Beats $(0.82) Estimate, Sales $5.14M Beat $1.17M Estimate; Cash, Cash Equivalents and Marketable Securities of $624M With Cash Runway into Late 2026
27 Feb 24
Earnings, News
Press releases
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1 Mar 24
Press Releases
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
Earnings, Press Releases
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
1 Feb 24
News, Press Releases
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2 Jan 24
News, Press Releases